You are here

  • Home
  • Archive
  • Volume 79, Issue 6
  • Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Citation Tools

Article menu

Download PDFPDF

Osteoarthritis
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Berenbaum F, Blanco FJ, Guermazi A, et al
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
Annals of the Rheumatic Diseases 2020;79:800-810.